Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Up 1.9%

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report)'s stock price was up 1.9% on Tuesday . The company traded as high as $43.71 and last traded at $43.67. Approximately 27,646 shares traded hands during trading, a decline of 96% from the average daily volume of 752,133 shares. The stock had previously closed at $42.87.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on RARE shares. JPMorgan Chase & Co. upped their price objective on Ultragenyx Pharmaceutical from $88.00 to $92.00 and gave the stock an "overweight" rating in a report on Monday, March 18th. Wedbush restated a "neutral" rating and set a $48.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday. Robert W. Baird lifted their price objective on Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the company an "outperform" rating in a research note on Tuesday, January 30th. Canaccord Genuity Group increased their target price on shares of Ultragenyx Pharmaceutical from $110.00 to $111.00 and gave the stock a "buy" rating in a research report on Wednesday, February 21st. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $107.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, April 5th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, Ultragenyx Pharmaceutical currently has an average rating of "Moderate Buy" and a consensus price target of $91.55.

Ultragenyx Pharmaceutical Stock Down 1.3 %

The firm has a market cap of $3.48 billion, a P/E ratio of -5.08 and a beta of 0.65. The business's 50 day moving average is $48.22 and its 200-day moving average is $43.39.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.52) EPS for the quarter, topping analysts' consensus estimates of ($1.65) by $0.13. Ultragenyx Pharmaceutical had a negative return on equity of 369.54% and a negative net margin of 139.70%. The business had revenue of $127.39 million during the quarter, compared to the consensus estimate of $119.38 million. During the same period last year, the firm earned ($2.16) earnings per share. The company's revenue for the quarter was up 23.3% compared to the same quarter last year. As a group, equities analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.34 earnings per share for the current year.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, Director Matthew K. Fust sold 12,195 shares of the firm's stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $50.88, for a total value of $620,481.60. Following the transaction, the director now owns 14,860 shares of the company's stock, valued at $756,076.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Ultragenyx Pharmaceutical news, Director Matthew K. Fust sold 12,195 shares of the firm's stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $50.88, for a total value of $620,481.60. Following the sale, the director now directly owns 14,860 shares in the company, valued at $756,076.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider John Richard Pinion sold 4,173 shares of the company's stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $53.76, for a total transaction of $224,340.48. Following the transaction, the insider now owns 89,268 shares of the company's stock, valued at approximately $4,799,047.68. The disclosure for this sale can be found here. Insiders have sold 31,974 shares of company stock worth $1,639,721 over the last ninety days. 6.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Covestor Ltd boosted its stake in Ultragenyx Pharmaceutical by 392.1% during the 3rd quarter. Covestor Ltd now owns 748 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 596 shares in the last quarter. UMB Bank n.a. lifted its holdings in shares of Ultragenyx Pharmaceutical by 118.8% in the fourth quarter. UMB Bank n.a. now owns 606 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 329 shares during the period. GAMMA Investing LLC boosted its stake in Ultragenyx Pharmaceutical by 622.3% during the first quarter. GAMMA Investing LLC now owns 1,004 shares of the biopharmaceutical company's stock valued at $47,000 after buying an additional 865 shares in the last quarter. Lazard Asset Management LLC grew its holdings in Ultragenyx Pharmaceutical by 36.6% during the first quarter. Lazard Asset Management LLC now owns 896 shares of the biopharmaceutical company's stock worth $64,000 after acquiring an additional 240 shares during the period. Finally, Comerica Bank raised its position in Ultragenyx Pharmaceutical by 24.7% in the fourth quarter. Comerica Bank now owns 1,331 shares of the biopharmaceutical company's stock worth $64,000 after acquiring an additional 264 shares in the last quarter. 97.67% of the stock is currently owned by institutional investors and hedge funds.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.